Trial · NCT02052778
Participant flow253
How many started, completed or left each group, period by period.
1 to 20 of 253
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 8 mg | 6 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 16 mg | 3 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 24 mg | 3 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 36 mg | 3 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 56 mg | 3 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 80 mg | 5 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 120 mg | 4 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 160 mg | 8 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QOD Dosing: 200 mg | 7 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QD Dosing: 4 mg | 4 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QD Dosing: 8 mg | 5 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QD Dosing: 16 mg | 14 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QD Dosing: 20 mg | 7 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Escalation: QD Dosing: 24 mg | 14 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Expansion Cohort 1 | 0 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Expansion: Cohort 2 | 0 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Expansion: Cohort 3 | 0 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Expansion: Cohort 4 | 0 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1:Dose Expansion: Cohort 5 | 0 | |
| Dose Escalation(Approximately 60 Months) | STARTED | Phase 1: Dose Expansion: Cohort 6 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02052778/flow